approval
saveRINVOQ (UPADACITINIB) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalRINVOQ (UPADACITINIB) — FDA approvalOct 10, 2025 · 356d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalAug 12, 2025 · 415d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 28, 2025 · 521d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalMar 26, 2025 · 554d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 888d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 888d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalNov 14, 2023 · 1052d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalJun 22, 2023 · 1197d ago
same company · ±60 days · 6
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 11, 2022
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalMay 11, 2022
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalMar 16, 2022
- approvalvenetoclax: VENCLEXTA (VENETOCLAX) — FDA approvalJun 15, 2022
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalJun 16, 2022
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalJun 16, 2022
comments(0)
5-min edit window · permanent after that